Search clinical trials for: BI 6727 (d1 and 15)

Total 1692 results

Boehringer Ingelheim

Completed

BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

Neoplasms

Belgium
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers

Neoplasms

Taiwan
Boehringer Ingelheim

Completed

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Neoplasms

Belgium
Boehringer Ingelheim

Completed

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Neoplasms

United States, Taiwan
Northwestern University
National Cancer Institute (NCI); National Comprehensive Cancer Network

Withdrawn

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia

United States
Boehringer Ingelheim

Completed

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Leukemia, Myeloid, Acute

Germany
Boehringer Ingelheim

Completed

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Neoplasms

Italy
Boehringer Ingelheim

Completed

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Neoplasms

Belgium
Fundación Santiago Dexeus Font

Recruiting

INtensity of OVarian Stimualtion and Euploid Embryos (INOVEE)

Fertility

Spain
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Bahamas, Canada
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Emory University
Georgia Center for Oncology Research & Education

Not yet recruiting

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Human Immunodeficiency Virus | Human Papilloma Virus | Anal Intraepithelial Neoplasia | High-Grade Squamous Intraepithelial Lesions

United States
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Assistance Publique - Hôpitaux de Paris

Recruiting

LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2 (LIPICOR)

SARS-CoV2 Infection

France
Hospices Civils de Lyon

Completed

Biomarkers for the Prognosis of Influenza in Children (BMIG)

Influenza

France
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
University of Alberta

Withdrawn

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Acute | Leukemia, Monocytic, Acute | Leukemia, Megakaryoblastic, Acute | Leukemia, Erythroblastic, Acute

Canada
H3 Biomedicine Inc.
Eisai Inc.

Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer | Hepatic Carcinoma

France, United States, Belgium, Spain, Taiwan, Korea, Republic of, Russian Federation, Canada, Italy, Singapore, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Fudan University

Unknown

Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer

Rectal Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Yonsei University

Unknown

Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer

Gastric Adenocarcinoma

Korea, Republic of
Massachusetts General Hospital
Boehringer Ingelheim

Withdrawn

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

AML

United States
Hawaii Biotech, Inc.

Completed

Study of HBV-001 D1 in Healthy Adults

Dengue Fever

United States
Shen Lin

Unknown

Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer

China
Boehringer Ingelheim

Completed

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)

Neoplasms

United States, Belgium, Netherlands, Germany, Spain, Australia, United Kingdom, Japan, France, Singapore, Hungary
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
National Cancer Institute (NCI)

Completed

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome | Adult T-Cell Lymphoma/Leukemia

United States
Boehringer Ingelheim

Active, not recruiting

Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Neoplasm Metastasis

United States, United Kingdom, Canada
Boehringer Ingelheim

Completed

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

Spain, United Kingdom, Italy, United States, Canada, Germany, Greece, Austria, Norway, France, Japan, Hungary, Poland, Finland
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
EVIVE Biotechnology

Completed

Trial to Compare the Efficacy and Safety of F-627 and GRAN® (F-627)

Breast Cancer

China
Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Terminated

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung

Netherlands
Masonic Cancer Center, University of Minnesota

Completed

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Acute Myelogenous Leukemia

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
Masonic Cancer Center, University of Minnesota

Completed

Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Boehringer Ingelheim

Completed

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Neoplasms

Korea, Republic of, Taiwan, Japan
Myrexis Inc.

Unknown

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Glioblastoma Multiforme

United States
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
Glycemic Index Laboratories, Inc
PepsiCo Global R&D

Completed

Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact (Solstice)

Diabetes Mellitus

Canada
University Hospital, Ghent

Completed

Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery. (SeqB vs SIB)

Radiotherapy After Breast Conserving Surgery

Belgium
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Routes of Immunization and Flu Immune Responses (FLUWAY)

Influenza

France
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Healthy

Germany
Northumbria University
Nektium Pharma SL

Completed

Acute Dose-ranging Effects of Mango Leaf Extract (Zynamite® 15%) on Cognitive Function and Cerebral Blood Flow

Cognitive Change

United Kingdom
OSE Immunotherapeutics
Boehringer Ingelheim

Active, not recruiting

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Solid Tumor, Adult

France, Belgium
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Neoplasms

Japan

3

Subscribe